Brokerages Anticipate Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) to Post ($0.32) Earnings Per Share
Shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Analysts have set a one year consensus price objective of $10.25 for the company and are expecting that the company will post ($0.32) earnings per share for the current quarter, according to Zacks. Zacks has also given Aralez Pharmaceuticals an industry rank of 87 out of 265 based on the ratings given to its competitors.
Several brokerages have weighed in on ARLZ. Guggenheim reiterated a “buy” rating and issued a $12.00 price objective on shares of Aralez Pharmaceuticals in a research report on Thursday, September 15th. Chardan Capital restated a “buy” rating and set a $10.00 target price on shares of Aralez Pharmaceuticals in a report on Friday, September 16th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/07/brokerages-anticipate-aralez-pharmaceuticals-inc-nasdaqarlz-to-post-0-32-earnings-per-share.html
Aralez Pharmaceuticals (NASDAQ:ARLZ) traded down 1.280% during mid-day trading on Friday, reaching $5.015. 149,365 shares of the company traded hands. Aralez Pharmaceuticals has a 12-month low of $3.10 and a 12-month high of $8.59. The stock’s market capitalization is $327.18 million. The company’s 50-day moving average is $5.30 and its 200-day moving average is $4.17.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.08. Aralez Pharmaceuticals had a negative net margin of 224.35% and a negative return on equity of 73.21%. The company earned $12.60 million during the quarter, compared to the consensus estimate of $9.70 million. The company’s quarterly revenue was up 142.3% compared to the same quarter last year. Equities analysts predict that Aralez Pharmaceuticals will post ($1.06) earnings per share for the current fiscal year.
In related news, Director Robert Paul Harris sold 150,000 shares of the company’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $5.82, for a total transaction of $873,000.00. Following the completion of the transaction, the director now owns 669,094 shares in the company, valued at $3,894,127.08. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 6.77% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Elk Creek Partners LLC boosted its stake in shares of Aralez Pharmaceuticals by 8.8% in the second quarter. Elk Creek Partners LLC now owns 1,514,918 shares of the company’s stock valued at $4,999,000 after buying an additional 122,172 shares during the last quarter. Paloma Partners Management Co purchased a new stake in shares of Aralez Pharmaceuticals during the second quarter valued at $475,000. Tiger Legatus Capital Management LLC boosted its stake in shares of Aralez Pharmaceuticals by 17.6% in the second quarter. Tiger Legatus Capital Management LLC now owns 1,500,000 shares of the company’s stock valued at $4,950,000 after buying an additional 225,000 shares during the last quarter. Janus Capital Management LLC boosted its stake in shares of Aralez Pharmaceuticals by 1.3% in the second quarter. Janus Capital Management LLC now owns 1,603,757 shares of the company’s stock valued at $5,292,000 after buying an additional 20,623 shares during the last quarter. Finally, Levin Capital Strategies L.P. purchased a new stake in shares of Aralez Pharmaceuticals during the second quarter valued at $221,000. Institutional investors own 49.63% of the company’s stock.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.